To the Editor, Vitamin K antagonists (VKA) perform their anticoagulant effect by inhibiting vitamin K epoxide reductase, an enzyme that recycles oxidized vitamin K to its reduced form. Vitamin K is a cofactor for the post-translational carboxylation of several vitamin K-dependent proteins. Consequently, VKA result in defective synthesis of the vitamin K-dependent clotting factors: factor (F) II, VII, IX, and X. The recommended method used for monitoring VKA is determination of the international normalized ratio (INR) which is derived from the prothrombin time (PT) [1] . This test is sensitive to the levels of FII, FVII and FX, but is not responsive to reduction of FIX, which can be detected by activated partial thromboplastin time (aPTT). APTT measures the efficacy of both the intrinsic and the common coagulation pathway and is also influenced by vitamin K-dependent clotting factors (FIX, FX and FII). Therefore, among patients treated with VKA, a prolonged aPTT is observed. The relationship between an elevated INR in a patient on VKA treatment with the aPTT is not known and probably depends on the FIX level. Very low FIX in patients on VKA treatment, due to mutation in the FIX gene, with prolonged aPTT have been described, but is very rare [2] . This relationship likely depends also on the combination of aPTT reagent and instrument utilized and aPTT reagents differ largely in sensitivity to coagulation factor deficiency [3] . Although aPTT measurement is not indicated in VKA monitoring, the aPTT is widely used as part of a coagulation screening panel. In case of VKA-treated patients a prolonged aPTT is often due to the VKA, although the measure of prolongation of aPTT in VKA-treated patients is unknown. Misinterpretation of a prolonged aPTT should be avoided and therefore the sensitivity of the aPTT reagent towards INR in AVK-treated patients can be informative.
In this study, we have evaluated the relationship between INR and aPTT in patients on VKA anticoagulant treatment and the sensitivity of three different aPTT reagents, PTT-A (Diagnostica Stago, Asnières-sur-Seine, Lupus anticoagulant (LA) was detected according to the SSC guidelines using the dilute Russell's Viper Venom Test (dRVVT) (LA screen and LA confirm, Life Diagnostics, DSRV, Clarkstons, MI, USA) and a sensitive aPTT assay (PTT-LA and Staclot ® LA, Diagnostica Stago) [4] . C-reactive protein (CRP) was measured on Cobas ® 8000 (Roche Diagnostics, Belgium).
Seven hundred samples were collected. In a first step the aPTT with the three different reagents and PT/INR were measured (Figure 1) . A Grubb's outlier test (α = 0.05) on bias between INR measured during the study and the routinely measured INR was performed to exclude samples (n = 45) influenced by the freezing/thawing cycle. Linear regression analysis between aPTT and INR (n = 655) was performed. Samples of patients with disproportionate aPTT were identified by using the 95% and 90% prediction limits (Figure 2 ). In total 55 outliers were identified, five samples with a disproportionate short aPTT and 50 with a disproportionate prolonged aPTT for corresponding INR. In Table 1 the mean aPTT of all samples within the prediction limits and the upper limit of aPTT was calculated for the three aPTT reagents for INR of 2, 3 and 4.
Next, we further analyzed the samples beyond the 90% prediction limit with at least one of the aPTT reagents.
Samples with a disproportional short aPTT (n = 5) were examined for FVIII and FIX activity. In four out of the five samples the elevated FVIII level > 150% (normal range, 60%-150%) could explain the disproportional short aPTT. One sample showed a normal FVIII activity of 103% and the FIX activity was low (23.3%) and thus could not explain the disproportion. FII, FX and FVII were, respectively, 46%, 28%, and 2%. FVII influences strongly the PT-INR [5] . The discrepancy between the relatively high FII and FX level and very low FVII level could explain the disproportional low aPTT (respectively, 67. Samples with disproportional prolonged aPTT (n = 50) were further analyzed for TT and anti-Xa activity to rule out the presence of heparin (UFH) or low molecular weight heparin (LMWH). In 37 out of 50 samples (74%) presence of UFH or LMWH was confirmed. We explored the remaining 13 out of 50 samples by consulting the medical and laboratory history of these patients and extra analyses. Five out of 13 samples showed the presence of LA. LA interferes with clotting in phospholipid dependent clotting tests, such as aPTT and explains the prolonged aPTT [4] . In four out of the 13 samples CRP was > 180 mg/dL coagulation tests by LA due to interference with accumulation of coagulation factors on negatively charged phospholipids [6, 7] . The influence is reagent dependent as observed in the present data and explains the disproportional prolonged aPTT with Cephascreen ® and PTT-A, reagents sensitive to high CRP concentration and not with C.K. Prest ® , a reagent insensitive for CRP interference [7] . Furthermore, we found one sample with a factor FXII deficiency.
For three out of the 13 samples we could not identify a cause for the disproportional prolonged aPTT (CRP In conclusion, the rate of aPTT prolongation in VKAtreated patients is reagent dependent. We calculated the expected prolongation of aPTT with three different reagents (PTT-A, C.K. Prest ® and Cephascreen ® ) for INR of 2, 3 and 4. An extensively prolonged aPTT in VKA-treated patients may not be due to VKA alone. Disproportional prolonged aPTT in patients on VKA treatment merit further attention and should be investigated to avoid misinterpretation. In 47 of the 50 samples (94%) we found another cause resulting in a prolonged aPTT: presence of UFH/LMWH (n = 37), LA (n = 5) high CRP (n = 4) and FXII deficiency (n = 1).
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